A Phase I, Open-Label, Multicenter, Dose Escalation and Expansion Study of HM97662 as a Single Agent in Patients With Advanced or Metastatic Solid Tumors
Latest Information Update: 08 May 2025
At a glance
- Drugs HM-97662 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Hanmi Pharmaceutical
Most Recent Events
- 30 Apr 2025 Planned number of patients changed from 140 to 170.
- 30 Apr 2025 Planned primary completion date changed from 1 Feb 2025 to 1 Jan 2028.
- 17 Sep 2024 Trial design presented at the 49th European Society for Medical Oncology Congress